Investor Overview

STOCK QUOTE

Exchange
NASDAQ GS
Last Price
$7.72
Change (%)
+0.25 (3.35%)

INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of patients' lives.

Using our proprietary sublingual spray technology and our capability to develop pharmaceutical cannabinoids, Insys addresses the clinical shortcomings of existing commercial products. Insys currently markets two products, SUBSYS®, a sublingual Fentanyl spray for breakthrough cancer pain launched in March of 2012, and SYNDROS®, the first and only FDA-approved liquid dronabinol for loss of appetite in AIDS patients and nausea and vomiting caused by anti-cancer medicine (chemotherapy). Please see full prescribing information for SUBSYS® and SYNDROS® including the boxed warning.

Our product pipeline is aimed at addressing conditions with unmet medical needs, such as refractory pediatric epilepsy (including childhood absence epilepsy and infantile spasms), the genetic disorder Prader-Willi syndrome, anorexia-associated weight loss in cancer patients, agitation in Alzheimer's disease, migraine, anaphylaxis (severe allergic reaction), acute pain, opioid dependence and reversal of opioid-induced respiratory depression.

 

Recent News

Aug 09 2018
INSYS Therapeutics Appoints Elizabeth Bohlen to Board of Directors
PHOENIX, Aug. 09, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the appointment of Elizabeth Bohlen as a new... 
Aug 08 2018
INSYS Therapeutics Reports Second Quarter 2018 Results
Focus remains on advancing pipeline across cannabinoid and spray platforms PHOENIX, Aug. 08, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids (CBD) ... 
Aug 08 2018
INSYS Therapeutics Reaches Agreement in Principle to Settle Department of Justice Investigation
Provisional Financial Settlement Terms Are Consistent with Previous Public Statements and Disclosures PHOENIX, Aug. 08, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmac... 
see all news

Receive Email Alerts

Sign Up Now

Upcoming Events

There are currently no events scheduled.

see all events